Perianal malignant nodular hidradenoma in HIV infected pregnant patient

Abstract

Malignant nodular hidradenoma (MNH) is a rare invasive tumour arising from eccrine sweat glands, with significant risk for local recurrence and distant metastases. Hidradenoma papilliferum is reported in pregnancy. To our knowledge this is the first MNH in a human immunodeficiency virus (HIV) infected pregnant woman. The patient presented with a painless perianal growth. Wide local excision was performed and the wound left to heal by secondary intension. The pathology report confirmed MNH. The patient has been followed for 14 months without evidence of recurrence. MNH should be considered in the differential diagnosis of similar lesions in HIV infected patients. Treatment for such HIV infected patients with MNH may be similar to that in immune-competent patients; they may benefit from a longer follow-up period.

Perineal Clear Cell Hidradenoma: A GATA3-positive Neoplasm With Potential for Misdiagnosis

“…Clear cell hidradenoma (CCH), also known as nodular hidradenoma, solid cystic hidradenoma, and eccrine acrospiroma is a rare benign skin adnexal neoplasm with a wide variety of histologic appearances that can mimic benign and malignant cutaneous and noncutaneous tumors (1). The lesion is most commonly located in the dermis of the head, upper extremities, and trunk but has been reported to occur in the vulva and perianal regions, as well as the breast (2)(3)(4)(5)(6). Malignant counterparts of CCH have also been reported (2,3,5).…”

“…The lesion is most commonly located in the dermis of the head, upper extremities, and trunk but has been reported to occur in the vulva and perianal regions, as well as the breast (2)(3)(4)(5)(6). Malignant counterparts of CCH have also been reported (2,3,5). GATA3 is an immunohistochemical marker with a high sensitivity for staining breast and urothelial carcinomas, but has been reported to react, albeit at a lower rate, with a variety of other tumors including transitional cell proliferations of the female genital tract and cutaneous neoplasms including hidradenomas (7)(8)(9).…”